HC Wainwright & Co. initiated coverage on Field Trip Health with a new price target
$FTRP
HC Wainwright & Co. initiated coverage of Field Trip Health with a rating of Buy and set a new price target of $20.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/22/2021 | $20.00 → $25.00 | Buy | HC Wainwright & Co. |
| 9/1/2021 | $20.00 | Buy | HC Wainwright & Co. |
TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (formerly, Field Trip Health Ltd., the "Company" or "Reunion"), a global leader in the discovery and development of innovative of psychedelic-inspired therapeutics for improved mental health outcomes, is pleased to announce that its common shares (the "Shares") will commence trading on the Toronto Stock Exchange ("TSX") under the ticker symbol "REUN" at the opening of the market on August 17, 2022. Trading of the Company's shares on the TSX represents the last step in the corporate reorganization that resulted in the spinout of the Company's former subsidiary, Field Trip Health & Wellness Ltd. ("FTHW") into a stand-alone
Completed corporate reorganization, separating the Field Trip Discovery and Field Trip Health divisions into two separate companies.Field Trip Discovery renamed Reunion Neuroscience Inc. ("Reunion" or the "Company"), and will remain listed on the NASDAQ Stock Market and Toronto Stock Exchange under new ticker symbol "REUN".Field Trip Health renamed Field Trip Health & Wellness Ltd. ("Field Trip H&W") and has received listing approval from the Toronto Stock Exchange Venture under new ticker symbol "FTHW".First day of trading for both Reunion and Field Trip H&W is August 17, 2022.On July 21, 2022, announced successful first dosings in the Company's Phase 1 Clinical Study of its first novel psy
- Field Trip Health Ltd. has been renamed "Reunion Neuroscience Inc." and remains listed on the NASDAQ Stock Market and Toronto Stock Exchange under the ticker symbol "FTRP" with such ticker symbol changing to "REUN"- Field Trip Health & Wellness Ltd. to be listed on the TSX Venture Exchange under ticker symbol "FTHW" - First day of trading for both Reunion and Field Trip Health & Wellness expected to occur on or about August 17, 2022 - Field Trip Health & Wellness Ltd. completes $19.9 million private placement financing TORONTO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., (formerly, Field Trip Health Ltd.) (TSX:FTRP, NASDAQ:FTRP) (the "Company"), and Field Trip Health &
6-K - Reunion Neuroscience Inc. (0001865482) (Filer)
6-K - Reunion Neuroscience Inc. (0001865482) (Filer)
6-K - Reunion Neuroscience Inc. (0001865482) (Filer)
HC Wainwright & Co. reiterated coverage of Field Trip Health with a rating of Buy and set a new price target of $25.00 from $20.00 previously
HC Wainwright & Co. initiated coverage of Field Trip Health with a rating of Buy and set a new price target of $20.00
TORONTO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX:FTRP, FTRP.WT, NASDAQ:FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today the lead indications for FT-104, its novel psychedelic compound in development, will be Treatment Resistant Depression (TRD) and Postpartum Depression (PPD). Field Trip today also announced that Anita H. Clayton, MD, Chair of Psychiatry and Neurobehavioral Sciences at the School of Medicine at the University of Virginia, has joined its Scientific Advisory board. Through Field Trip Discovery, its drug development division, Field Trip is developing next-generation psychedelic molecu
Completed corporate reorganization, separating the Field Trip Discovery and Field Trip Health divisions into two separate companies.Field Trip Discovery renamed Reunion Neuroscience Inc. ("Reunion" or the "Company"), and will remain listed on the NASDAQ Stock Market and Toronto Stock Exchange under new ticker symbol "REUN".Field Trip Health renamed Field Trip Health & Wellness Ltd. ("Field Trip H&W") and has received listing approval from the Toronto Stock Exchange Venture under new ticker symbol "FTHW".First day of trading for both Reunion and Field Trip H&W is August 17, 2022.On July 21, 2022, announced successful first dosings in the Company's Phase 1 Clinical Study of its first novel psy
TORONTO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX:FTRP, NASDAQ:FTRP) ("Field Trip" or the "Company"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for its fiscal 2023 first quarter for the three-month period ended June 30, 2022, after market close on Monday, August 15, 2022. The Company will conduct a conference call and webcast to discuss its results the following morning, Tuesday, August 16, 2022 at 8:30 a.m. ET. To access the call, please dial 1-877-407-9716 (within the U.S.) or 1-201-493-6779 (outside the U.S.) and provide conference ID 13731900. A live webcast of the conferenc
Completed strategic review and announced intention to separate the Field Trip Discovery and Field Trip Health divisions into two independent public companies.Earned patient services revenues of $1.7 million in fiscal fourth quarter, an increase of 26.7% over the prior quarter and 228% year over year. Full year patient services revenue was $4.9 million, up from $0.96 million in the same period of the prior year.At March 31, 2022, Field Trip had approximately $63.7 million in unrestricted cash and cash equivalents.On April 5, 2022, granted U.S Patent for the first novel psychedelic molecule in development, molecule FT-104, for exclusive rights for the composition of matter, use and manufacturi